Can a switch to a cheaper drug keep leukemia at bay?

This study looked at whether people with chronic myeloid leukemia (CML) who achieved a good response to the drug nilotinib could safely switch to a different drug, imatinib, to maintain that response. The goal was to see if imatinib could keep the cancer under control while potentially reducing side effects and costs. Only 13 people took part, and the study focused on maintaining a specific type of remission called complete cytogenetic response.